Introduction: Radiosynovectomy (RS), which uses beta particle-emitting radiocolloids, has proven highly effective in significantly reducing the occurrence of haemarthroses and breaking the cycle of bleeding and synovitis. This study now presents the long-term outcomes of repeated RS in individuals with haemophilia. Materials and Methods: Repeated RS was administered to 48 joints in 37 people with haemophilia (PwHs) diagnosed with chronic haemophilic synovitis. The frequency of bleeding episodes was meticulously recorded during the 6-month periods preceding and following each of the initial and subsequent RS procedures. Treatment failure was designated by the necessity for additional RS injections. Results: The results for 48 joints were analysed. The mean bleeding frequency of the joints was 12.5 +/- 7.29 (median 10) within the last 6 months in the pre-treatment evaluation and after the treatment, the mean bleeding frequency of the joints decreased to 2.25 +/- 3.82 (median 0.5) for the first 6 months (p < 0.001) after the first RS. The mean survival of the first intervention was 40.52 +/- 33.79 months (range, 1-124 months). In the second RS, the mean bleeding frequency of the joints was 10.29 +/- 7.66 (median 8) within the last 6 months in the pre-treatment evaluation and after the treatment, and the mean bleeding frequency of the joints decreased to 0.93 +/- 1.69 (median 0) for the first 6 months (p < 0.001). The survival rate of the second RS was 94% at 12 months, and 87% at 36 months. Conclusion: Repeated RS was proven to be an effective and safe treatment for Pwh with recurrent bleeding episodes during long-term follow up. Thirty-six months survival rate was 87% (42 of 48 joints).
机构:
Eli Lilly & Co, Lilly Biomed, Indianapolis, IN 46285 USAEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan
Iikuni, Noriko
Hamaya, Etsuro
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, JapanEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan
Hamaya, Etsuro
Nihojima, Shigeru
论文数: 0引用数: 0
h-index: 0
机构:
Chugai Pharmaceut Co Ltd, Drug Safety Div, Chuo Ku, Tokyo, JapanEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan
Nihojima, Shigeru
Yokoyama, Shunji
论文数: 0引用数: 0
h-index: 0
机构:
Chugai Pharmaceut Co Ltd, Drug Safety Div, Chuo Ku, Tokyo, JapanEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan
Yokoyama, Shunji
Goto, Wakana
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly Japan KK, Dev Ctr Excellence Asia Pacific, Lilly Res Labs Japan, Kobe, Hyogo 6510086, JapanEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan
Goto, Wakana
Taketsuna, Masanori
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly Japan KK, Dev Ctr Excellence Asia Pacific, Lilly Res Labs Japan, Kobe, Hyogo 6510086, JapanEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan
Taketsuna, Masanori
Miyauchi, Akimitsu
论文数: 0引用数: 0
h-index: 0
机构:
Miyauchi Med Ctr, Takatsuki, Osaka, JapanEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan
Miyauchi, Akimitsu
Sowa, Hideaki
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, JapanEli Lilly Japan KK, Dev Ctr Excellence, Lilly Res Labs Japan, Chuo Ku, Kobe, Hyogo 6510086, Japan